FibroGen Appoints David DeLucia as Chief Financial Officer
FibroGen (NASDAQ: FGEN) has appointed David DeLucia as its new Chief Financial Officer, effective December 16, 2024, succeeding Juan Graham. DeLucia, who previously served as FibroGen's Vice President of Corporate Financial Planning and Analysis, Investor Relations, and Treasury, will lead the company's global finance organization.
DeLucia brings nearly 15 years of financial leadership experience in life sciences, including previous roles at TherapeuticsMD and JP Morgan Asset Management. The appointment comes as FibroGen advances its development of FG-3246, a first-in-class ADC targeting CD46, and its companion diagnostic FG-3180, while building on roxadustat's performance.
FibroGen (NASDAQ: FGEN) ha nominato David DeLucia come nuovo Chief Financial Officer, con efficacia dal 16 dicembre 2024, succedendo a Juan Graham. DeLucia, che in precedenza ha ricoperto il ruolo di Vice Presidente della Pianificazione e Analisi Finanziaria, Relazioni con gli Investitori e Tesoreria di FibroGen, guiderà l'organizzazione finanziaria globale dell'azienda.
DeLucia porta con sé quasi 15 anni di esperienza nella leadership finanziaria nel settore delle scienze della vita, comprese esperienze precedenti presso TherapeuticsMD e JP Morgan Asset Management. La nomina arriva mentre FibroGen avanza nello sviluppo di FG-3246, un ADC di prima classe che mira a CD46, e il suo diagnostico companion FG-3180, mentre si basa sulle performance di roxadustat.
FibroGen (NASDAQ: FGEN) ha nombrado a David DeLucia como su nuevo Director Financiero, efectivo a partir del 16 de diciembre de 2024, sucediendo a Juan Graham. DeLucia, quien previamente se desempeñó como Vicepresidente de Planificación y Análisis Financiero Corporativo, Relaciones con Inversores y Tesorería de FibroGen, liderará la organización financiera global de la empresa.
DeLucia aporta casi 15 años de experiencia en liderazgo financiero en ciencias de la vida, incluidos roles anteriores en TherapeuticsMD y JP Morgan Asset Management. El nombramiento se produce a medida que FibroGen avanza en el desarrollo de FG-3246, un ADC de primera clase dirigido a CD46, y su diagnóstico companion FG-3180, mientras se basa en el rendimiento de roxadustat.
FibroGen (NASDAQ: FGEN)은 데이비드 드루시아를 새로운 최고 재무 책임자로 임명하였으며, 이는 2024년 12월 16일부터 시행됩니다. 드루시아는 후안 그레이엄의 후임으로 활동하게 됩니다. 드루시아는 이전에 FibroGen의 기업 재무 계획 및 분석 부사장, 투자자 관계 및 재무 관리로 재직했던 경험이 있으며, 회사의 글로벌 재무 조직을 이끌게 됩니다.
드루시아는 생명 과학 분야에서 거의 15년의 재무 리더십 경험을 가지고 있으며, TherapeuticsMD와 JP Morgan Asset Management에서의 경력도 포함됩니다. 이번 임명은 FibroGen이 CD46을 목표로 하는 1급 ADC인 FG-3246와 그에 따른 진단 기구인 FG-3180 개발을 진행하는 가운데 이루어졌습니다. 또한, roxadustat의 성능을 기반으로 하고 있습니다.
FibroGen (NASDAQ: FGEN) a nommé David DeLucia en tant que nouveau Directeur Financier, à partir du 16 décembre 2024, succédant à Juan Graham. DeLucia, qui a précédemment occupé le poste de Vice-Président de la Planification et de l'Analyse Financière, des Relations avec les Investisseurs et de la Trésorerie chez FibroGen, dirigera l'organisation financière mondiale de l'entreprise.
DeLucia apporte près de 15 ans d'expérience en leadership financier dans les sciences de la vie, y compris des rôles précédents chez TherapeuticsMD et JP Morgan Asset Management. La nomination intervient alors que FibroGen fait progresser le développement de FG-3246, un ADC de première classe ciblant le CD46, et son test de diagnostic compagnon FG-3180, tout en s'appuyant sur la performance de roxadustat.
FibroGen (NASDAQ: FGEN) hat David DeLucia zum neuen Chief Financial Officer ernannt, der am 16. Dezember 2024 in Kraft tritt und Juan Graham nachfolgt. DeLucia, der zuvor als Vizepräsident für Unternehmensfinanzierungsplanung und -analyse, Investor Relations und Treasury bei FibroGen tätig war, wird die globale Finanzorganisation des Unternehmens leiten.
DeLucia bringt fast 15 Jahre Erfahrung in der finanziellen Führung im Bereich der Lebenswissenschaften mit, einschließlich früherer Positionen bei TherapeuticsMD und JP Morgan Asset Management. Die Ernennung erfolgt, während FibroGen die Entwicklung von FG-3246, einem erstklassigen ADC, der auf CD46 abzielt, und seinem Begleitdiagnosetests FG-3180 vorantreibt, während es auf den Leistungen von roxadustat aufbaut.
- Internal promotion ensures continuity and deep understanding of company operations
- Appointee brings 15 years of relevant life sciences financial leadership experience
- New CFO has been instrumental in company's recent transformation into a lean organization
- None.
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024.
Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen’s global finance organization. He has most recently served as FibroGen’s Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury.
“Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabilities required to lead our finance organization and be a key member of our leadership team,” said Thane Wettig, Chief Executive Officer of FibroGen. “His deep understanding of all aspects of our business, along with his proven track record and strategic insights will be invaluable in his new role as CFO as we advance FG-3246, a first-in-class ADC targeting CD46, and its companion diagnostic FG-3180, while further building on the strong performance of roxadustat.”
“I am thrilled to take on the role of CFO at FibroGen and to help lead the company at this important time,” said DeLucia. “With our recent transformation into a lean and focused organization, I believe we are well positioned for an exciting future and look forward to continued execution on our strategic vision to bring novel therapies forward for cancer and cancer-related conditions.”
Mr. DeLucia has nearly 15 years of financial leadership and experience within the life sciences industry. Prior to joining FibroGen in 2022, he held positions of increasing responsibility at TherapeuticsMD, overseeing Financial Planning and Analysis, Corporate Development, and Investor Relations. Earlier in his career, he was a buy-side investor at JP Morgan Asset Management, covering small and mid-cap healthcare companies.
Mr. DeLucia holds the Chartered Financial Analyst® designation and a dual degree of Bachelor of Business Administration in Finance & Accounting and Bachelor of Science in Economics from the University of Michigan - Stephen M. Ross School of Business.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET imaging agent, FG-3180. In addition, FibroGen’s research and development portfolio includes two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.
Forward-Looking Statements
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the potential clinical or commercial success of FibroGen products and product candidates, and statements about FibroGen’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
Contact:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
ir@fibrogen.com
FAQ
When does David DeLucia start as CFO of FibroGen (FGEN)?
What was David DeLucia's previous role at FibroGen (FGEN)?
What key products is FibroGen (FGEN) currently developing?
Who did David DeLucia replace as CFO at FibroGen (FGEN)?
What is David DeLucia's professional background before joining FibroGen (FGEN)?
